ISB News

ISB Innovations: Ultrasound-Based Tumor Biopsies

John Chevillet is a postdoc in the Hood Lab at Institute for Systems Biology in Seattle.
Name:

John Chevillet, PhD

Lab:

Hood

Research:

I am trying to develop an ultrasound-based method to take a sample from a tumor, thus replacing needle biopsies. An ultrasound-based method would minimize complications, better diagnose cancers, and direct the use of targeted therapies for personalized medicine.

Wish List:

If I had $10,000, I could analyze the blood specimens we currently have for cancer dna to demonstrate what this method can tell us about the mutations driving a tumor. If I had $100,000, I could analyze a wide spectrum of molecules (DNA, RNA and protein) and start to define a biomarker signature panel that could be used as a foundation for a test more accurate than what we have now. If I had $1 million, I could partner with physicians and patients to test this method.

How you can help:

Watch this short video and click the button at the end of the video. Or donate now.

If you have questions about this project or would like to speak directly with our researchers, contact us.

 

Recent Articles

  • 2024 Year in Review

    Reflecting on the past year, ISB has a lot to celebrate: groundbreaking research published in leading scientific journals, well-earned promotions, widespread media coverage, and more. Enjoy our year-in-review roundup highlighting some of the important, interesting, and impactful highlights of 2024.

  • My Digital Gut

    ISB Named Winner of 2024-2025 Amazon Web Services IMAGINE Grant for Nonprofits

    ISB has been selected as a winner of the 2024 Amazon Web Services (AWS) IMAGINE Grant. The grant will support ISB’s continued development of My Digital Gut, an online decision-support platform that will help make microbiome-informed nutrition and healthcare personalized, predictive, and preventive. 

  • ISB-Developed MetaboCore Offers Precision Cancer Care Faster Than Ever 

    ISB Associate Professor Dr. Wei Wei and his colleagues have developed a promising new companion diagnostic tool called MetaboCore to help physicians quickly select the most effective systemic therapy for each cancer patient.